Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01089270

Enrollment

Registered

2010-03-18

Start date

2010-03-31

Completion date

Unknown

Last updated

2010-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson, fdg pet-ct, i123 dat scan, first degree relatives of diagnosed Parkinson patients, with no clinical evidence of movement disorders

Brief summary

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms. Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes. The examination results will be given to the participants by a doctor from the neurology department.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy first degree relatives of diagnosed Parkinson patients

Exclusion criteria

* patients unable to understand and sign an informed consent * minors * people with psychiatric disorders or a history of major head trauma

Countries

Israel

Contacts

Primary ContactEinat Even-sapir, PhD, MD

evensap@tasmc.health.gov.il972-3-6974444

Backup ContactAyelet Kurzband, BA

ayeletk@tasmc.health.gov.il972-3-6974444

Outcome results